India's drug regulator has initiated a nationwide crackdown on smuggled and unapproved medicines, intensifying enforcement efforts across borders and supply chains. This move comes amid a rise in illicit cross-border drug inflows, with the Central Drugs Standard Control Organization (CDSCO) flagging 90 unapproved fixed-dose combination (FDC) drugs being sold without FDA clearance, including diabetes pills, paracetamol combinations, and multivitamins, according to livemint.com.
The CDSCO has expanded surveillance mechanisms to monitor drug imports and domestic distribution channels more closely. Officials highlighted that the crackdown targets medicines lacking regulatory approval, aiming to curb the circulation of potentially unsafe drugs. The enforcement includes coordination with customs and logistics authorities to intercept smuggled consignments and enforce compliance with drug safety standards, as detailed by livemint.com.
This crackdown addresses growing concerns over the safety and efficacy of medicines entering the Indian market through unauthorized channels. The presence of unapproved FDC drugs poses health risks and undermines regulatory frameworks. The move aligns with global trends where regulators tighten controls to ensure drug quality and patient safety. The CDSCO's actions follow increased reports of illicit drug inflows that threaten public health, as reported by livemint.com.
The CDSCO's identification of 90 unapproved FDC drugs marks a critical step in safeguarding India's pharmaceutical supply chain. Enforcement actions are ongoing, with authorities enhancing border checks and supply chain audits to prevent further circulation of these medicines, according to livemint.com.